Abstract Salvianolic acid A (SalA) is an effective compound extracted from traditional Chinese medicine Salvia miltiorrhiza Bunge. The Forkhead box O3a (FOXO3a) signaling pathway plays crucial roles in the modulation of ischemia-induced cell apoptosis. However, no information about the regulatory effect of SalA on FoxO3a is available. To explore the anti-cerebral ischemia effect and clarify the therapeutic mechanism of SalA, SH-SY5Y cells and Sprague-Dawley rats were applied, which were exposed to oxygen glucose deprivation/reoxygenation (OGD/R) and middle cerebral artery occlusion/ reperfusion (MCAO/R) injuries, respectively. The involved pathway was identified using the specific inhibitor LY294002. Results showed that SalA concentration-dependently inhibited OGD/R injury triggered cell viability loss. SalA reduced cerebral infarction, lowered brain edema, improved neurological function, and inhibited neuron apoptosis in MCAO/R rats, which were attenuated by the treatment of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) specific inhibitor LY294002. SalA time-and concentration-dependently upregulated the phosphorylation levels of protein kinase B (AKT) and its downstream protein FOXO3a. Moreover, the nuclear translocation of FOXO3a was inhibited by SalA
Introduction
Stroke is considered to be one of most severe life-threatening diseases with high incidence, high mortality, and high disability worldwide 1, 2 . Ischemic stroke accounts for 87% of all stroke types 3, 4 . Complicated mechanisms and pathophysiological events have been implicated to involve in ischemic stroke injury including oxidative stress, inflammatory response, calcium overload, excitotoxicity, etc 5 . Besides the Food and Drug Administration (FDA) approved tissue plasminogen activator (tPA), few other therapeutic agents are clinical available throughout the world. In addition, thrombolytic therapy by tPA only benefits a small proportion of clinical patients due to its narrow thrombolysis window and high risk of hemorrhage injury 6, 7 . The development of new therapeutic agent is imperative.
The Forkhead box O (FOXO) proteins family is a group of transcription factors, regulating various genes and proteins expression, such as BCL-like protein 11 (BIM) and matrix metalloproteinases (MMP). FOXO family transcription factors, including FOXO1, 3, 4, and 6, are reported to be the important downstream proteins of phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B (PI3K/AKT) pathway [8] [9] [10] [11] [12] , one of the most vital regulators in cell survival, autophagy, apoptosis, proliferation and differentiation [13] [14] [15] [16] . Kinase in this pathway could phosphorylate Forkhead box O3a (FOXO3a) to induce its redistribution to cytoplasm and reduce its transcriptional activity. FOXO3a has been proved to be a transcriptional target in apoptosis regulation in vivo and in vitro, which might be a promising target for neuroprotection 8, 17 . Salvianolic acid A (SalA) is a polyphenol compound extracted and purified from Salvia miltiorrhiza Bunge (Fig. 1A) . SalA is one of the major effective components of several traditional Chinese medicine (TCM) preparations for the clinical treatment of cardiovascular and cerebrovascular diseases [18] [19] [20] [21] [22] [23] [24] . It was reported that SalA could activate AKT/mammalian target of rapamycin C1 (mTORC1) signaling to initiate NF-E2 related factor 2/heme oxygenase-1 (NRF2/HO-1) signal transduction, thus fighting against H 2 O 2 -upregulated cellular oxidative stress 25 . SalA pretreatment significantly upregulated the phosphorylation levels of AKT in ischemia/reperfusion injured diabetic rats 26 . SalA alleviated ischemic brain injury in mice partially through the activation of PI3K/AKT signaling 27 . Thus, SalA might activate PI3K/AKT signaling during ischemic injury. But whether SalA could regulate FOXO3a/BIM-induced cell apoptosis was unknown. This work was designed to research the potential therapeutic effect of SalA on oxygen glucose deprivation/reoxygenation (OGD/R)-injured SH-SY5Y cells, as well as on middle cerebral artery occlusion/reperfusion (MCAO/R)-injured rat brain, and especially to find out whether FOXO3a/BIM pathway was involved in the neuroprotective mechanism of SalA.
Materials and methods

Reagents and chemicals
SalA (HPLC purity 499%) was obtained from Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Figure 1 Chemical structure of SalA (A) and its protective effect against OGD/R-induced SH-SY5Y cells viability loss (B) and (C). Cell morphology was obtained by an inverted microscope. Data was expressed as mean7SD of 4 independent tests. siRNA or control siRNA for 6 h, the normal culture medium was added again before OGD/R stimulation.
MTT assay
Firstly, SH-SY5Y cells were seeded and cultured in 96-well culture plates with 8 Â 10 3 cells per well. After the above mentioned OGD/R injury and SalA treatment procedure, MTT method was carried out to test cell viability. Shortly, each well was added with 0.5 mg/mL MTT reagent, and then incubated at 37 1C for 4 h. Then, remove the cell culture supernatant, and add 100 μL of DMSO to each well. Stir the plate for 15 min on a microplate shaker. Finally, determine the absorbance value of each well by a microplate reader at 490 nm. The cell viability of each well was calculated according to the measured absorbance value.
Establishment of animal model and grouping
Sprague-Dawley rats (male, 240-260 g) were purchased from Beijing Vital River Experimental Animal Co., Ltd. (Beijing, China; certificate No. SCXK2016-0006). Great efforts have been given to minimize the experiment-induced discomfort and the physical and emotional pain of rats. All the animal related procedures were reviewed and approved for further research by the Institutional Animal Care and Use Committee of the Institute of Materia Medica, CAMS & PUMC (Beijing, China). The MCAO/R model was established according to the method previously reported 28 . Isoflurane was used to anesthetize the rats. After fixed in a supine position, rats underwent the surgery to reveal the right common carotid artery (CCA), external carotid artery (ECA), as well as the internal carotid artery (ICA). Then a filament with a diameter of 0.2 mm was inlet from ECA of rat into ICA and finally got to MCA. After 1.5 h of ischemia, the monofilament was carefully pulled out to achieve cerebral reperfusion. Animals were randomly grouped as follows: sham operation group, I/R model group, I/RþSalA groups (5, 10 and 20 mg/kg) and I/RþSalAþLY294002 group (20 mg/kg SalA and LY294002), n ¼ 40 for each group. LY294002 was dissolved in 4% DMSOþ30% PEG 300þ5% Tween 80þddH 2 O to a final concentration of 10 mmol/L. 10 μL LY294002 (10 mmol/L) was pre-injected into the ventricular space of the ischemic hemisphere 1 h before ischemia as mentioned before 29 . SalA was dissolved in normal saline. After the reperfusion, rats were injected intravenously with vehicle or SalA twice a day for 3 days. The followed tests were performed on the fourth day after the reperfusion.
Neurological deficit scores
Neurological deficit scores evaluation was used for functional assessment. Rat neurological function was tested by an investigator who was blinded to the grouping with a five-point evaluation method as mentioned before 30 . Rats with no observed neurological deficit got a score of 0; rats unable to fully extend left forepaw got a score of 1; rats that circled to left got a score of 2; rats that fell to left got a score of 3; rats unable to walk spontaneously and with depressed levels of consciousness got a score of 4. The rats with a score of 0 point indicating no neurological deficit were screened out of the further study. And the rats with a score of 4 point indicating extremely severe damage were also excluded from the further study.
Determination of infarct volume by TTC staining
Cerebral infarct volume is an important evaluation factor for the efficacy of anti-cerebral ischemia reperfusion drug. In brief, rats were sacrificed after the evaluation of neurological function. The rat brain was separated quickly and placed in a freezer at -20 1C. After 20 min, the brain tissue was taken out at room temperature and dissected into slices of 2-mm thickness. Then slices were quickly placed into TTC solution (0.5%) to react for 30 min, flipped every 5 min, and finally fixed with 4% paraformaldehyde. As a result, the normal area in slice was rose-red, while the infarct area was white without staining. Brain slices of each rat were arranged neatly and photographed. A researcher who was blinded to the rats grouping outlined and calculated the infarct areas and whole areas using ImageJ software (Version 1.51, National Institutes of Health; Bethesda, MA, USA). The infarct volume was calculated by multiplying the infarct area and the thickness (2 mm) of each slice and displayed as a percentage of whole brain volume.
Immunofluorescence assay
The FOXO3a nuclear translocation in vitro was observed via immunofluorescence assay. After OGD/R stimulation and SalA treatment, cells for fluorescence imaging were fixed using 4% paraformaldehyde. And then they were permeabilized using 0.3% Triton X-100. After blocked by 5% BSA, the primary antibody against FOXO3a was added and incubated at 4 1C overnight. Then Alexa Fluor-488 (1:500)-conjugated secondary antibody was added and incubated for 1 h. Finally, Hoechst 33258 was added and incubated for 30 min. The fluorescent images for the observation of nuclear translocation were taken under a microscope. The brain tissue for frozen sections was placed in a 4% paraformaldehyde solution and fixed. After that, frozen sections were prepared into 5 μm thickness. For TUNEL and NeuN or GLUT1 double-labeled staining. Proteinase K was firstly incubated. Then the buffer solution, reaction solution, saline sodium citrate, 0.5% Triton X-100 and 10% goat serum were added following steps and incubated as planned. Then cells were treated with primary antibody against NeuN or GLUT1 overnight, and the secondary antibody for 1 h. The fluorescent images of TUNEL were taken under a microscope.
For FOXO3a and NeuN staining, brain slices were firstly treated with 0.5% Triton X-100, and then treated with 10% goat serum. The primary antibodies against FOXO3a and NeuN were then used and reacted overnight. Then the secondary antibodies were used and reacted. Finally, after DAPI treatment, the fluorescent images of FOXO3a and NeuN staining were taken under a microscope.
Western blot analysis
SH-SY5Y cells or brain tissues were both extracted using RIPA buffer. The rat cortex and hippocampus were carefully and rapidly separated from brains on ice. Each 0.1 g tissue was added with 1 mL RIPA buffer and homogenized. The homogenate was then lysed on ice for 30 min. A BCA protein assay kit was used for the protein quantification. Proteins were loaded and separated using SDS-PAGE method, then transferred onto a PVDF membrane. After being blocked with 5% BSA for 2 h, proteins were treated with primary antibodies against p-FOXO3a, FOXO3a, p-AKT, AKT, BIM, cleaved caspase 3 and GAPDH at 4 1C overnight. Then the secondary antibodies against HRP-conjugated rabbit or mouse IgG were added to the system. An ECL method was used for image developing. Band density was calculated with the ImageJ software.
Statistical analysis
The results were shown as mean7standard deviation (SD). SPSS software (version 16.0, Chicago, IL, USA) was used for data analysis. The significance between groups was carried out by one-way ANOVA analysis followed by Tukey's Multiple Comparison post hoc test. A P valueo0.05 was calculated to be statistically significant.
Results
Effect of SalA on OGD/R-induced SH-SY5Y cells viability loss
OGD/R stimulation resulted in severe cell damage and cell viability loss (Po0.001), while SalA treatment significantly inhibited OGD/R-induced SH-SY5Y cells viability loss at the concentration range of 0.05-5 μmol/L in a concentration dependent manner as shown in the MTT assay and under the inverted microscope. The in vitro concentration 5 μmol/L showed maximal neuroprotection effect and was selected for further study.
SalA increased Akt and FOXO3a phosphorylation, inhibited BIM and cleaved caspase 3 expression in vitro
FOXO3a signaling participates in cell apoptosis regulation. As shown in Fig. 2 , OGD/R injury downregulated the phosphorylation levels of AKT and FOXO3a significantly (Po0.001). SalA treatment (0.5 and 5 μmol/L) inhibited the downregulation of FOXO3a phosphorylation (Po0.01 and Po0.001). OGD/R stimulation downregulated the ratios of p-mTOR/mTOR and p-GSK3β/GSK3β. But SalA could not upregulate both ratios of p-mTOR/mTOR and p-GSK3β/GSK3β. So, further studies were focused on the regulation of p-FOXO3a/ FOXO3a induced by SalA. Meanwhile, the phosphorylation levels of AKT were upregulated by SalA treatment (0.05, 0.5 and 5 μmol/L). In addition, OGD/R injury significantly upregulated the expression of BIM and cleaved caspase 3 (Po0.001), and SalA treatment (0.5 and 5 μmol/L) downregulated the expression of BIM and cleaved caspase 3.
SalA increased AKT and FOXO3a phosphorylation in a time-and concentration-dependent manner
The above results indicated PI3K/AKT and FOXO3a signaling might mainly contribute to the protective effect of SalA on cells (Fig. 3) .
SalA activated FOXO3a/BIM signaling through AKT pathway
The above studies indicated that SalA could upregulated the phosphorylation levels of AKT and FOXO3a in SH-SY5Y cells. To find out whether PI3K/AKT contributed to SalA-induced FOXO3a phosphorylation, LY294002 was used. Firstly, cells were pre-treated with LY294002 (10 μmol/L) for 30 min before subjected to OGD/R stimulation and SalA treatment. Then the MTT assay was carried out. The pre-incubation of LY294002 significantly reversed the protective effects of SalA on cell viability (Fig. 4A, Po0.001 ). In addition, preincubation with LY294002 significantly reversed SalA-induced AKT phosphorylation, as well as FOXO3a phosphorylation (Fig. 4B and C, Po0.001). As shown in Fig. 4D , SalA treatment inhibited the nuclear translocation of FOXO3a, which could be reversed by the interference of LY294002. To evidence FOXO3a/BIM pathway by interfering FOXO3a, FOXO3a siRNA was introduced. It was found that the nuclear FOXO3a level was significantly downregulated by siRNA interference, which triggered the downregulated expression of BIM protein ( Fig. 4E and F) . These results indicated that PI3K/AKT pathway mainly contributed to the protective effects of SalA and SalA-induced FOXO3a phosphorylation in SH-SY5Y cells. The phosphorylation of FOXO3a reduced the nuclear FOXO3a level, which further resulted in the downregulation of BIM.
3.5. SalA inhibited MCAO/R injury-induced FOXO3a nuclear translocation and upregulated AKT phosphorylation in ischemic rat brain cortex and hippocampus I/R injury downregulated the cortex phosphorylation levels of AKT and FOXO3a (Fig. 5A-C) , while SalA treatment (20 mg/kg) significantly increased the phosphorylation level of FOXO3a (Po0.01). In addition, the phosphorylation of AKT was also upregulated by SalA treatment (Po0.01) in MCAO/R rats. The upregulated phosphorylation of FOXO3a and AKT was reversed by LY294002 interference (Po0.01) in the brain cortex region. MCAO/R injury also downregulated the levels of p-AKT and p-FOXO3a in the rat brain hippocampus region (Fig. 5D-F) . SalA treatment (20 mg/kg) could significantly upregulate the phosphorylation level of FOXO3a in the hippocampus. The phosphorylation level of AKT was also upregulated by SalA treatment in MCAO/R rat hippocampus region. But the upregulated phosphorylation of FOXO3a and AKT was reversed by LY294002 interference in the hippocampus (Po0.01). Immunofluorescence assay further verified that SalA treatment inhibited the nuclear translocation of FOXO3a both in the brain cortex and hippocampus regions, which was reversed by the interference of LY294002 (Fig. 5G and H) .
3.6. SalA inhibited BIM and cleaved caspase 3 expression in rat brain cortex and hippocampus subjected to MCAO/R injury MCAO/R injury significantly upregulated the expression of BIM and cleaved caspase 3 in both rat brain cortex and hippocampus (Fig. 6, Po0.001) , while SalA treatment significantly inhibited the expression of BIM and cleaved caspase 3 in the brain cortex and hippocampus. Po0.01 and *** 3.7. SalA reduced infarct volume, neurological deficit scores, and inhibited neuron and endothelial cells apoptosis in MCAO/R rats TUNEL staining showed cell apoptosis rate. MCAO/R injury increased the apoptosis rate of neurons in the rat brain cortex (Po0.001), SalA treatment (20 mg/kg) decreased neuron apoptosis rate compared with MCAO/R group in cortex, while LY294002 treatment reversed the apoptosis inhibition effects of SalA ( Fig. 7A and B) . Fig. 7C and D showed that MCAO/R injury also significantly upregulated the neuron apoptosis rate in the rat brain hippocampus region (Po0.001), SalA treatment (20 mg/kg) reduced neuron apoptosis compared with MCAO/R group in the hippocampus, which was also reversed by LY294002 treatment. Fig. 7E and F showed that MCAO/R injury significantly upregulated the apoptosis rate of GLUT1 positive cells in the rat brain ischemic penumbra region (Po0.001), SalA treatment (20 mg/kg) significantly inhibited GLUT1 positive cells apoptosis compared with MCAO/R group, which was also reversed by LY294002 treatment. TTC staining was used to assess brain infarction. As shown in Fig. 7G and H, there was almost no infarction in sham group, MCAO/R group developed severe infarction (Po0.001). SalA decreased the percent of infarct volume significantly (Po0.001). LY294002 partially reversed the downregulation effects of SalA on brain infarction (Po0.001). Neurological deficit scores were assessed on the fourth day after reperfusion. MCAO/R caused severe neurological impairment compared with sham operation group (Po0.001). SalA (20 mg/kg) reduced the neurological deficit scores significantly (Po0.001). And LY294002 also reversed the effects of SalA on neurological deficit scores (Po0.01).
Discussion
In the present study, it was found that SalA treatment significantly protected SH-SY5Y cells against OGD/R-induced cell death and fought against I/R injury in SD rats. The protective effects of SalA were achieved via the inhibition of the FOXO3a/BIM pathway, which further inhibited cell apoptosis. This was the first study to reveal that the neuroprotective effect of SalA was at least partially related to its regulation on FOXO3a/BIM pathway.
The FOXO family of proteins plays key roles in cell growth, development, differentiation, metabolism and apoptosis 31 . FOXO3a has three sites (T32, S253, and S315) with strongest evidence of being phosphorylated by Akt 32 . According to previous studies, PI3K/AKT is involved in the defense against cerebral ischemia-reperfusion injury 33, 34 . FOXO3a could be phosphorylated by the PI3K/AKT pathway 35 . The phosphorylation of FOXO3a blocks its nuclear localization and reduces the transcription of the target genes. Once translocated into the nucleus, FOXO3a could bind to Bim promoter to promote BIM protein expression, thus initiating the apoptosis pathway 36 . The specific mechanism of SalA on FOXO3a/BIM signaling has not yet been clarified before. Therefore, studies were carried both in vivo and in vitro to investigate whether SalA can participate in the protective effect against I/R injury through the FOXO3a/BIM signaling pathway. SH-SH5Y cells were used to establish OGD/R stimulation model in vitro. The protective mechanism of SalA on neurons was proved by MTT assay. It was found that SalA protected cells from OGD/R injury via increasing cell viability. BCL-2 protein family plays key role in apoptosis regulation and serves as the major regulator of mitochondrial function and the release of apoptotic factors 37, 38 . BIM is an important member of BH3-only BCL-2 family 39 . It is an important pro-apoptotic protein 40, 41 . The pro-apoptotic activity is controlled by both transcriptional regulation and post-translational modification 42, 43 . SalA could promote the phosphorylation of FOXO3a and reduce the expression of proapoptotic protein BIM.
To clarify the role of AKT/FOXO3a/BIM signaling in neuroprotection, the specific inhibitor LY294002 was investigated. The experimental results showed that the protective effects of SalA in vitro could be reversed by LY294002 treatment, and the SalA-induced upregulation of p-AKT and p-FOXO3a were also been inhibited significantly. The phosphorylation of FOXO3a leaded to the change of its cellular localization. OGD/R stimulation reduced the phosphorylation of FOXO3a, facilitating its translocation into the nucleus. SalA could inhibit the nuclear translocation of FOXO3a, while LY294002 reversed the effects of SalA to keep FOXO3a in the nucleus. What's more, the protective effect of SalA on cell viability was also reversed by the treatment of the PI3K inhibitor LY294002. FOXO3a siRNA interference also significantly downregulated the nuclear FOXO3a level, which triggered the downregulated expression of BIM protein. Taken together, the PI3K/AKT/FOXO3a/BIM pathway is confirmed to participate in the protective mechanism of SalA against OGD/R injury. Our previous study found that SalA alleviated renal injury through anti-inflammation in systemic lupus erythematosus induced by pristane in BALB/c mice 44 . SalA could alleviate the ischemic injury via the inhibition of soluble epoxide hydrolase 45 . SalA was also found to alleviate mice brain ischemic damage via anti-inflammation, anti-apoptosis and promoting neurogenesis 27 . The pharmacokinetic study of SalA showed that it could pass across the blood-brain barrier (BBB) to play the protective effect. It was found that I/R injury caused serious damage to the BBB. The serious damage of BBB facilitated the passage of SalA through BBB to the brain. The brain exposure to SalA was significantly higher in the I/R rats than in the sham controls, suggesting that the enhanced exposure to SalA contributed to its cerebral protective effect. It was found that the peak concentration of SalA in brain after 10 mg/kg injection was about 1.5 μg/mL 46 . In our paper, 20 mg/kg SalA was applied, the peak concentration of SalA in brain was supposed to be about 3 μg/mL. That means the 5 μmol/L concentration (2.47 μg/mL for unit conversion) in vitro could be reached at the target site in vivo if 20 mg/kg SalA is applied. In our present study, SalA was proved to increase the phosphorylation levels of AKT and FOXO3a in both the cortical and hippocampal neurons. The FOXO3a/BIM signaling was proved to be involved in the protective mechanism of many other agents against various injury 11, 47, 48 . Our study for the first time clarified the regulation effect of SalA on FOXO3a/BIM signaling. The expression of BIM and cleaved caspase 3 were significantly increased by the ischemia reperfusion injury, while SalA treatment downregulated the expression of BIM and cleaved caspase 3. The TUNEL staining results also showed that SalA could reduce the apoptosis rate of neurons, but the above antiapoptosis effect and FOXO3a phosphorylation effect of SalA on MCAO/R rats were reversed by LY294002 intervene.
In conclusion, our present study reported for the first time that SalA attenuated cerebral ischemia-reperfusion injury at least partially via the AKT/FOXO3a/BIM pathway. The regulation of FOXO3a/BIM signaling by SalA suggested a novel promising approach for neuroprotection and provided new insights about the protective mechanism of SalA. 
